AU2018231408B2 - Phage therapy - Google Patents

Phage therapy Download PDF

Info

Publication number
AU2018231408B2
AU2018231408B2 AU2018231408A AU2018231408A AU2018231408B2 AU 2018231408 B2 AU2018231408 B2 AU 2018231408B2 AU 2018231408 A AU2018231408 A AU 2018231408A AU 2018231408 A AU2018231408 A AU 2018231408A AU 2018231408 B2 AU2018231408 B2 AU 2018231408B2
Authority
AU
Australia
Prior art keywords
bacteriophage
bacteriophages
sequence
aureus
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2018231408A
Other languages
English (en)
Other versions
AU2018231408A1 (en
Inventor
Hélène Blois
Cindy FEVRE
Mathieu Medina
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phaxiam Therapeutics SA
Original Assignee
Erytech Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erytech Pharma SA filed Critical Erytech Pharma SA
Publication of AU2018231408A1 publication Critical patent/AU2018231408A1/en
Application granted granted Critical
Publication of AU2018231408B2 publication Critical patent/AU2018231408B2/en
Priority to AU2023251526A priority Critical patent/AU2023251526A1/en
Assigned to ERYTECH PHARMA reassignment ERYTECH PHARMA Request to Amend Deed and Register Assignors: PHERECYDES PHARMA
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/40—Viruses, e.g. bacteriophages
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/50—Isolated enzymes; Isolated proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10131—Uses of virus other than therapeutic or vaccine, e.g. disinfectant
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10231—Uses of virus other than therapeutic or vaccine, e.g. disinfectant
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10271—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Agronomy & Crop Science (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pest Control & Pesticides (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
AU2018231408A 2017-03-08 2018-03-07 Phage therapy Ceased AU2018231408B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023251526A AU2023251526A1 (en) 2017-03-08 2023-10-20 Phage therapy

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17305245.7A EP3372085A1 (en) 2017-03-08 2017-03-08 Phage therapy
EP17305245.7 2017-03-08
PCT/EP2018/055629 WO2018162566A1 (en) 2017-03-08 2018-03-07 Phage therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023251526A Division AU2023251526A1 (en) 2017-03-08 2023-10-20 Phage therapy

Publications (2)

Publication Number Publication Date
AU2018231408A1 AU2018231408A1 (en) 2019-09-12
AU2018231408B2 true AU2018231408B2 (en) 2023-07-27

Family

ID=58536918

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018231408A Ceased AU2018231408B2 (en) 2017-03-08 2018-03-07 Phage therapy
AU2023251526A Abandoned AU2023251526A1 (en) 2017-03-08 2023-10-20 Phage therapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023251526A Abandoned AU2023251526A1 (en) 2017-03-08 2023-10-20 Phage therapy

Country Status (9)

Country Link
US (2) US11690885B2 (enExample)
EP (2) EP3372085A1 (enExample)
JP (2) JP7492337B2 (enExample)
CN (2) CN110545670B (enExample)
AU (2) AU2018231408B2 (enExample)
BR (1) BR112019018593A2 (enExample)
CA (1) CA3054874A1 (enExample)
IL (2) IL288099B (enExample)
WO (1) WO2018162566A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3372085A1 (en) 2017-03-08 2018-09-12 Pherecydes Pharma Phage therapy
WO2021146598A1 (en) * 2020-01-17 2021-07-22 Second Genome, Inc. Methods and compositions for treating atopic dermatitis
IL295408A (en) * 2020-02-18 2022-10-01 Armata Pharmaceuticals Inc Bacteriophage preparations for the treatment of staphylococcus infection
CZ309429B6 (cs) * 2020-03-31 2023-01-04 MB PHARMA s.r.o Lyofilizovaná testovací sada ke stanovení antimikrobiální biologické účinnosti fágových přípravků na bakterii Staphylococcus aureus
EP4132552A2 (en) * 2020-04-06 2023-02-15 Adaptive Phage Therapeutics, Inc. Method for treating implantable device infections
EP4337764A1 (en) * 2021-05-12 2024-03-20 Biomx Ltd. Staphylococcus bacteriophage and uses thereof
FR3161553A1 (fr) * 2024-04-30 2025-10-31 Hospices Civils De Lyon Compositions, en particulier, pharmaceutiques de bactériophages de la classe des Caudoviricetes , procédé et utilisations associés

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130142820A (ko) * 2012-06-20 2013-12-30 한국외국어대학교 연구산학협력단 스태필로코커스 아우레우스의 박테리오파아지 및 그 용도

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1690194A (zh) * 2004-04-26 2005-11-02 何俭 一株治疗金黄色葡萄球菌感染的噬菌体
GB0800149D0 (en) * 2008-01-04 2008-02-13 Novolytics Ltd Improved host range phage
EP2103308A1 (de) * 2008-03-20 2009-09-23 PhytoLine GmbH Verfahren zur Herstellung eines Gemisches von Bakteriophagen und deren Verwendung für die Therapie von Antibiotika-resistenten Staphylococcen
US7745194B2 (en) * 2008-09-16 2010-06-29 Intralytix, Inc. Staphylococcus aureus: bacteriophage and uses thereof
US8043613B2 (en) * 2009-02-12 2011-10-25 Intron Biotechnology, Inc. Podoviriedae bacteriophage having killing activity specific to Staphylococcus aureus
EP2865383A1 (en) 2013-10-25 2015-04-29 Pherecydes Pharma Phage therapy of pseudomonas infections
EP2893933A1 (en) 2014-01-10 2015-07-15 Pherecydes Pharma Phage Therapy of E coli infections
EP3018201A1 (en) 2014-11-07 2016-05-11 Pherecydes Pharma Phage therapy
CN104845942A (zh) * 2015-04-22 2015-08-19 上海交通大学 可裂解多种耐药性金黄色葡萄球菌的噬菌体及其分离方法和用途
WO2017015652A1 (en) 2015-07-23 2017-01-26 Enbiotix, Inc. Bacteriophage for treating staphylococcus infections
CN105567647B (zh) * 2015-11-06 2019-06-11 中国海洋大学 一株耐甲氧西林金黄色葡萄球菌噬菌体及其抑菌应用
EP3372085A1 (en) 2017-03-08 2018-09-12 Pherecydes Pharma Phage therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130142820A (ko) * 2012-06-20 2013-12-30 한국외국어대학교 연구산학협력단 스태필로코커스 아우레우스의 박테리오파아지 및 그 용도

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HSIEH, S.-E. et al., 'Genomic analysis of Staphylococcus phage Stau2 isolated from medical specimen', Virus Genes. 2015, Vol. 52, No. 1, pp. 107-116 *

Also Published As

Publication number Publication date
IL288099A (en) 2022-01-01
CN114107220A (zh) 2022-03-01
US12280080B2 (en) 2025-04-22
US20200030392A1 (en) 2020-01-30
JP7492337B2 (ja) 2024-05-29
CA3054874A1 (en) 2018-09-13
EP3592150A1 (en) 2020-01-15
WO2018162566A1 (en) 2018-09-13
IL268905A (en) 2019-10-31
AU2018231408A1 (en) 2019-09-12
JP2024105630A (ja) 2024-08-06
JP2020510024A (ja) 2020-04-02
IL268905B (en) 2021-12-01
AU2023251526A1 (en) 2023-11-16
CN114107220B (zh) 2025-01-10
BR112019018593A2 (pt) 2020-04-28
EP3372085A1 (en) 2018-09-12
CN110545670A (zh) 2019-12-06
US11690885B2 (en) 2023-07-04
IL288099B (en) 2022-07-01
CN110545670B (zh) 2021-11-23
US20240024391A1 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
DK3209381T3 (en) COMPOSITIONS COMPREHENSIVE BAKERY STUES
RU2725726C2 (ru) Бактериофаги, фаговые пептиды и способы их применения
AU2018231408B2 (en) Phage therapy
CN108359643B (zh) 新型金黄色葡萄球菌噬菌体及其组合物和应用
KR20200062184A (ko) 게놈을 변형시키기 위한 조성물 및 방법
KR101986442B1 (ko) 류머티스성 관절염용 바이오마커 및 이의 용도
KR102360880B1 (ko) 황색포도상구균 유래 점보박테리오파지 PALS2의 엔도라이신 LysPALS21
AU2025203392A1 (en) Therapeutic bacteriophage compositions
CN112243377A (zh) 用于治疗和预防细菌相关的癌症的噬菌体
KR20240021274A (ko) 반코마이신 내성 장구균에 대한 박테리오파지
AU2012335397B2 (en) Novel bacteriophages
AU2018256922B2 (en) Targeted gene disruption methods and immunogenic compositions
KR101993123B1 (ko) 신규한 병원성 대장균 특이 박테리오파지 eco5 및 이를 포함하는 항균 조성물
KR20220043584A (ko) 신규한 스타필로코커스균 특이 박테리오파지 opt-sc01 및 이를 포함하는 항균 조성물
JP2001292771A (ja) アブラムシ共生バクテリアのゲノムｄｎａ
KR102418861B1 (ko) 포도상구균에 대한 사멸능을 갖는 박테리오파지
KR102334893B1 (ko) 신규한 캠필로박터균 특이 박테리오파지 opt-cj1 및 이를 포함하는 항균 조성물
KR102723118B1 (ko) 스타필로코커스균 특이 박테리오파지 kmsp1 및 이를 포함하는 항균 조성물
CN114410591B (zh) 一种耐酸耐高温的金黄色葡萄球菌噬菌体及其组合物、试剂盒及其应用
KR102066898B1 (ko) 신규한 장알균 특이 박테리오파지 ef5 및 이를 포함하는 항균 조성물
CN115397447A (zh) 用于治疗葡萄球菌感染的噬菌体组合物
HK40083362A (en) Bacteriophage compositions for treating staphylococcus infection
HK40042802A (en) Bacteriophage for treatment and prevention of bacteria-associated cancers

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: ERYTECH PHARMA

Free format text: FORMER NAME(S): PHERECYDES PHARMA

MK14 Patent ceased section 143(a) (annual fees not paid) or expired